Publications
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Principles of treatment of patients with early forms of myelodysplastic syndrome2013 | First Faculty of Medicine
- Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports2012 | First Faculty of Medicine
- 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity2012 | First Faculty of Medicine
- Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation2011 | First Faculty of Medicine
- Current therapeutic approaches in myelodysplastic sydrome2009 | Publication without faculty affiliation
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
Loading network view...
